Given the speculations that SGLT2 inhibitors may increase the risk of thromboembolism due to the increase in haematocrit and blood viscosity, we also looked at the composite of arterial and venous thrombosis rates associated with SGLT2 inhibitor use. Here, SLC5A2 is linked to Thromboembolism.